eligibility_summary
Eligibility: Multiple myeloma with measurable disease (SPEP ≥0.5 g/dL, UPEP ≥200 mg/24h, or FLC ≥10 mg/dL with abnormal ratio). Part 1: 2–4 prior lines, Part 2: 1–3, include ≥1 IMiD and ≥1 PI. ECOG 0–1, prior toxicities ≤Grade 1. Exclude other plasma cell disorders, major cardiac disease, SCT <12 wks/active GVHD, active infection, other malignancy <3 yrs, prior BCMA/CD3 or iberdomide/mezigdomide, strong CYP3A inhibitors/inducers, investigational drug <30 d, or no VTE prophylaxis.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1b study in relapsed/refractory multiple myeloma testing: 1) Elranatamab (PF-06863135): a subcutaneous bispecific T‑cell–engaging antibody that binds BCMA on malignant plasma cells and CD3 on T cells to redirect T‑cell cytotoxicity. 2) Iberdomide (CC‑220/BMS‑986382): an oral cereblon E3 ligase modulator (CELMoD) that promotes degradation of Ikaros/Aiolos (IKZF1/3), enhancing T‑ and NK‑cell activation, IL‑2 production, and exerting direct anti‑myeloma activity. Cells/pathways targeted: BCMA+ plasma cells, CD3+ T cells, cereblon ubiquitin ligase pathway (IKZF1/3), boosting antitumor immune responses.